Urine neutrophil gelatinase-associated lipocalin as a biomarker in different renal problems

Didem TURGUT1,*, Serhan Vahit PIŞKINPAŞA2, Ezgi COŞKUN YENİGÜN3, Nihal AYDEMİR1, Fatih DEDE3

1 Division of Nephrology, Department of Internal Medicine, Başkent University Ankara Hospital, Ankara, Turkey
2 Department of Nephrology, İskenderun State Hospital, İskenderun, Turkey
3 Department of Nephrology, Ankara Numune Education and Research Hospital, Ankara, Turkey

* Correspondence: didemturgut@yahoo.com

1. Introduction
In some renal function problems, clinicians may not understand whether a patient had acute, subacute, or chronic kidney injury [1–3]. Knowing the duration and severity of the problem’s onset narrows the spectrum of the patients who may benefit from early interventions. Besides, it prevents clinicians from unnecessary workups. Contrary to popular myth, sCr, serum urea, and urine output are suboptimal functional markers to estimate the onset and type of kidney injury. However, uNGAL can predict acute kidney impairment in the early phase, and can assess etiology, severity, or clinical outcomes of AKI [4–8]. uNGAL tested in multiple studies of patients with AKI, but its role in postrenal causes is not clear. In some postrenal AKI conditions, it is not apparent whether the obstruction is chronic or acute, if it is not total. And the precise timing of removal of the obstruction is not visible. In this study, we aimed to determine the accuracy of uNGAL as a marker of underlying AKI etiologies who admitted to the hospital. We objected to estimating a cut-off value for uNGAL to understand whether kidney problem is acute or not, especially in a postrenal setting.

2. Materials and methods
2.1. Study design
We performed a prospective study with patients admitted to Ankara Numune Education and Research Hospital and referred to the department of nephrology during the three months. We enrolled patients in four groups: (1) patients with postrenal AKI; (2) patients with AKI other than postrenal causes; (3) stable chronic kidney disease; and (4) healthy subjects. A renal function assessment was carried out by measuring serum creatinine (sCr) and uNGAL at the time of diagnosis [0th min (T0)]. We followed the study group for three months.

Results: At the time of diagnosis, sCr (T0) was highest in the postrenal AKI and AKI groups in contrast to stable chronic kidney disease patients and healthy subjects (P < 0.001), as expected. T0 median uNGAL was highest in the postrenal group (P < 0.001). Area under curve (AUC) of uNGAL to estimate postrenal AKI presence was 0.957 (95% CI, 0.897–1.000; P < 0.001). The cut-off point of uNGAL was 42.625 ng/mL for this estimation.

Conclusion: Patients with AKI must be classified according to the underlying etiologies as soon as possible. uNGAL may be useful to estimate the etiologies, and whether the problem is acute or chronic in the course. In postrenal kidney problems, to plan the urgency of the urologic procedures, it is crucial.

Keywords: Acute kidney injury, urinary neutrophil gelatinase-associated lipocalin (uNGAL), postrenal, cut-off value

Received: 16.02.2020 • Accepted/Published Online: 08.09.2020 • Final Version: 22.10.2020

This work is licensed under a Creative Commons Attribution 4.0 International License.
2. Increase in sCr to ≥ 1.5 times baseline (which is known or presumed to have occurred within the prior seven days),
3. Urine volume < 0.5 mL/kg/h for 6 h [10].

Patients without known baseline sCr were not classified as having AKI. All patients with postrenal AKI and AKI were in stage 3 AKI [11]. sCKD was defined as a reduced estimated GFR of <60 mL/min/1.73 m² before admission (≥3 months) and no change from baseline during the hospitalization period [12]. The Charlson comorbidity index (CCI) was used to measure patients’ comorbidities [13]. Exclusion criteria for the general study population were age ≤18 or > 75 years old, pregnancy, and/or any infectious condition.

2.2. Patient population

pAKI group: Seventeen patients were enrolled in the group. Patients were selected due to AKI criteria and ultrasound (USG) findings. All patients had bilateral grade 2–3 hydroureteronephrosis on the USG, and none of them were anuric. After a urethral catheter inserted into each patient, all patients were evaluated with an urologist concerning for percutaneous nephrostomy need. Interventional radiologists placed a percutaneous nephrostomy tube into each of the 17 patients at the end of the evaluation. Using the Seldinger technique, a tube ranging from 8–12F was placed with USG. Placement of the nephrostomy catheter time was considered as the 0th min (T0), and blood samples (sCr) and urine specimens for NGAL analysis were collected at the same time as 0th min evaluation (T0 sCr). Patients with unilateral ureteral dilation or with known vesicoureteral reflux were excluded.

AKI group: Twenty patients were enrolled in this group. Patients were selected based on AKI criteria. AKI was defined as a new-onset increase in sCr [10]. The examination time by a nephrologist was accepted as T0 time, and blood samples (T0 sCr) and voided urine specimen for NGAL (T0 uNGAL) analysis were collected.

CKD group: Twenty-two patients were enrolled in this group. All patients were had stable sCr for >3 months and had been admitted to hospital for reasons other than kidney problems. Patients presented with stage 3–4 CKD. The nephrologist’s evaluation was accepted as T0 time, and blood samples (T0 sCr) and voided urine specimens for NGAL (T0 uNGAL) analysis were collected.

Control group: A group of 23 healthy subjects between 18 and 75 years old were prescreened by history and laboratory tests (blood, urine, and renal USG assessment) to exclude any preexisting urological or nephrological issues. They were recruited to provide voided bladder urine specimens for NGAL analysis.

2.3. Laboratory measurements

Baseline renal function by SCr, estimated glomerular filtration rate (eGFR), medical history, and demographic characteristics were obtained from electronic hospital records. A prospective renal function assessment was carried out by measuring sCr at 0 and 48 h, and at 1 and 3 months later (T0, T48, T1, and T3, respectively) from admission. uNGAL was measured at T0 (as mentioned above) from all study groups. Urinary samples for NGAL measurements were collected in ethylene diamine tetraacetic acid (EDTA) tubes and centrifuged at 3000 × g for 5 min. Supernatants were quickly frozen at −80 °C. uNGAL was measured using Human Lipocalin-2/NGAL ELISA kits (Biovendor GmbH, Heidelberg, Germany, RD191102200R) following the manufacturer’s instructions exactly. All resulting values in the samples were in the range of the standard curve provided by the manufacturer.

2.4. Statistical analysis

Data analyses were performed using the computer program SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Statistical analysis was performed using the one-way ANOVA for parametric data, and Kruskal–Wallis for nonparametric data. When the null hypothesis for these tests rejected, posthoc tests were used to find the differences. As posthoc tests, Tukey–Kramer, and six pairwise comparisons with Bonferroni correction were used. Differences between the groups were analyzed by Friedman's analysis of variance (ANOVA) for repeated measures. The receiver operating characteristic (ROC) curve was used to determine an uNGAL level that estimates AKI etiology. We assessed ROC curves and calculated the area under the curve (AUC), including 95% confidence intervals (CI). Estimated cut-off values were determined with the Youden's index. Univariate linear regression models were used to estimate uNGAL correlations with the first and third-month serum creatinine levels after the AKI period. A value of P = 0.05 was considered significant.

3. Results

3.1. Patient characteristics

A total of 82 subjects were enrolled in the study. Seventeen patients with pAKI, 20 patients with AKI, 22 patients with sCKD, and 23 healthy subjects were analyzed. Six patients had hemodialysis (HD) in the pAKI group, and three patients had HD in the AKI group. None of the patients had renal replacement treatment (RRT) by the one- and/or three-month follow-up examination. Median CCI was higher in the pAKI group with respect to AKI and sCKD patients (P < 0.001). T0 sCr was higher in pAKI, AKI, and sCKD patients, but there was no statistical difference between the pAKI and AKI groups (Table 1). sCr changes during follow-up are summarized in Figure 1. The urinary tract obstructions in pAKI were due to several reasons: (1) 7/17 cases of bladder cancer (41.1%); (2) 4/17 cases of prostate cancer (23.5%); and (3) 6/17 miscellaneous causes of obstruction (35.4%) as retroperitoneal fibrosis and post
radiation. The AKI group was composed of prerenal or intrinsic etiologies without any surgical history.

3.2. Discriminative capability of uNGAL and cut-offs for renal function problems

T0 median uNGAL was highest in the pAKI group. When we compare the groups for T0 uNGAL, there was a statistical difference between the pAKI and control group (98.7 and 13.7, respectively; P < 0.001), pAKI and CKD groups (98.7 and 31.9, respectively; P < 0.001), pAKI and AKI groups (98.7 and 57.8, respectively; P = 0.0016), and AKI and control groups (57.8 and 13.7, respectively; P < 0.001). The differences, however, between the sCKD and control groups (31.9 and 13.7, respectively; P = 0.212) and AKI and sCKD groups (57.8 and 31.9, respectively; P = 0.578) were not statistically significant (Table 1).

In the ROC curve analysis, the AUC of uNGAL for estimating pAKI was 0.957 (95% CI, 0.897–1.000; P < 0.001). According to Youden’s index, the cut-off point was 42.625, and the sensitivity and specificity were 0.94% and 0.91%, respectively, according to Youden’s index. The AUC of uNGAL for estimating AKI was 0.885 (95% CI, 0.781–0.988; P < 0.001). According to Youden’s index, the cut-off point was 26.205, and the sensitivity and specificity were 0.90% and 0.82%, respectively (Table 2). The ROC curves are presented as Figures 2–4.

Table 1. Patient characteristics and laboratory findings.

|                  | pAKI (n = 17) | AKI (n = 20) | sCKD (n = 22) | Control (n = 23) | P       |
|------------------|---------------|--------------|---------------|------------------|---------|
| Age, years       | 64.6 ± 10.5   | 60.3 ± 18.9  | 63.7 ± 11.2   | 32.9 ± 9.9       | NS      |
| Women, n (%)     | 6 (35.3%)     | 9 (45.0%)    | 12 (54.5%)    | 11 (47.8%)       | NS      |
| CCI (min-max)    | 6 (0–10)      | 2 (0–10)     | 5 (2–8)       | 0                |         |
| Hemodialysis, n (%) | 6             | 3            | 0             | 0                |         |
| Laboratory values (min-max) |
| T0 serum cr (mg/dL) | 6.30 (2.40–11.30) | 5.15 (2.20–13.20) | 1.50 (1.00–3.40) | 0.80 (0.60–1.00) | <0.001^a |
| T48 serum cr (mg/dL) | 2.00 (1.40–6.50)  | 2.50 (1.10–10.80) | 1.70 (0.80–4.20) | 1.35 (0.60–11.40) |          |
| T1 serum cr (mg/dL) | 1.70 (0.80–4.20)  | 1.35 (0.60–11.40) | 1.50 (1.10–3.00) | 0.80 (0.50–1.00) | NS      |
| T3 serum cr (mg/dL) | 1.60 (0.50–4.30)  | 1.30 (0.50–7.40) | 1.70 (1.00–3.10) | 0.90 (0.08–1.00) | NS      |
| T0 uNGAL ng/mL (min-max) | 98.7 (32.2–137) | 57.8 (5.2–121.0) | 31.9 (23.4–47.2) | 13.7 (1.2–42.1) | <0.001^b |

AKI: Acute kidney injury, pAKI: Postrenal acute kidney injury, CCI: Charlson comorbidity index, sCKD: Stabil chronic kidney disease, cr: Creatinine, GFR: Glomerular filtration rate, SD: Standard deviation, uNGAL: Urinary neutrophil gelatinase-associated lipocalin.

^aAfter the Bonferroni correction of P < 0.0083; pAKI-CKD, pAKI-control, and AKI-control are significantly different. But pAKI-AKI are similar (P = 0.152).

^bAfter the Bonferroni correction of P < 0.0083; pAKI-CKD, pAKI-AKI groups, and AKI-control groups were significantly higher.
We created simple linear regression models for uNGAL to predict sCr after one month of the AKI period (T1) and sCr after the third month of the AKI period (T3). Although there was statistically significant correlation, R-squared ($R^2$) was 10.5% for uNGAL as an independent predictor for T1 ($P < 0.001$) and 16.9% for T3 ($P < 0.001$).

4. Discussion

Discrimination of underlying etiologies of AKI remains challenging in patients with multiple comorbidities and those who are critically ill. In this study, we investigated whether uNGAL has an additive value to differentiate sCr elevations concerning AKI etiologies. uNGAL has been studied extensively in different AKI models [12,14–16]. Singer et al. studied uNGAL for the diagnosis of intrinsic and prerenal AKI, and they found that an uNGAL level >104 µg/L indicated intrinsic AKI (likelihood ratio 5.97). In the same study, it was also presented that uNGAL independently predicted the composite outcome after correcting for demographics, comorbidities, creatinine, and RIFLE (risk, injury, failure, loss of kidney function, end-stage disease) class [17]. In postrenal settings, studies related to uNGAL are limited. Urbschat et al. investigated uNGAL and kidney injury molecule-1 (KIM-1) in acute postrenal impairment. In this study, 53 patients with a proven diagnosis of acute unilateral renal colic and 52 control patients were included. Mean sCr levels of patients were higher compared to the control group (1.11 mg/dL versus 0.92 mg/dL; $P < 0.001$). Serum NGAL ($P < 0.001$) and uNGAL ($P < 0.001$) were both increased in the obstructive nephropathy group [18]. In this study, although ureteral obstructions were not total or bilateral, the increase in NGAL levels was a good biomarker for the kidney problem rather than the increase in sCr. There are some studies involving pediatric patients; that all

Table 2. AUC for uNGAL estimating the type of kidney problem.

|       | ROC-AUC (SE) | 95% CI          | P      | Cut-off ng/mL | Sensitivity % | Specificity % |
|-------|-------------|-----------------|--------|---------------|---------------|---------------|
| pAKI  | 0.957 (0.031) | 0.897–1.000     | <0.001 | 42.625        | 0.94          | 0.91          |
| AKI   | 0.885 (0.053) | 0.781–0.988     | <0.001 | 26.205        | 0.90          | 0.82          |
| sCKD  | 0.760 (0.074) | 0.615–0.905     | 0.003  | 25.180        | 0.68          | 0.82          |

AKI: Acute kidney injury, pAKI: Postrenal acute kidney injury, sCKD: Stable Chronic kidney disease, ROC-AUC: Receiver operating characteristic curve-area under the curve, CI: Confidence interval, SE: Standard error, uNGAL: Urinary neutrophil gelatinase-associated lipocalin.
demonstrated that uNGAL level was found to be increased in congenital hydronephrosis [19,20].

To our knowledge, our study is the first one that used uNGAL as a urinary biomarker of AKI in different etiologies, concomitantly. Additionally, we studied the uNGAL levels in the setting of an acute bilateral urinary obstruction to discriminate the direct effect of obstruction on uNGAL levels. In the study, uNGAL was highest in patients with bilateral urinary obstruction (pAKI) compared to patients with prerenal-intrinsic AKI or sCKD. The difference in uNGAL between pAKI-AKI groups was not related to the severity of the AKI stage since all patients in the two groups were with stage 3 AKI. It is likely to speculate that an increase in uNGAL is related to mainly tubular function problems rather than a parenchymal injury or a chronic course. In an experimental model of unilateral ureteral obstruction study, authors showed histologically that NGAL protein synthesis significantly increased in the dilated thick ascending limb of Henle. NGAL found in the urine was retained considerably in the swollen pelvis of the ligated kidney [21], demonstrating the role of NGAL in postrenal AKI. This finding suggests that NGAL was more strongly synthesized in damaged epithelia. Our results correlated with this knowledge in which a significant increased uNGAL was associated with obstruction rather than intrinsic or prerenal conditions.

In the studies related to cut-off levels of uNGAL to predict severity, there are heterogeneous results. In our research, the uNGAL cut-off value was highest in the postrenal group (42.625 ng/mL). Wasilewska et al. presented a study, including children with obstructive nephropathy. They found that increase in uNGAL levels during the AKI course was associated with worsening obstruction, and it was independent of an increase in creatinine [19]. Since our entire pAKI patient group had a total bilateral urinary obstruction, it is likely that as uNGAL increases in the postrenal course, obstruction gets severe needing immediate urologic intervention. Our presented cut-off levels were lower than in other studies [4, 22,23], which would be related to a higher variability in the assay types used. In correlation analysis, we aimed to find whether spot uNGAL levels might show the renal prognosis after three months. We showed a significant but weak correlation between uNGAL levels and follow-up sCr levels (R² 10.5% and 16.9%, for the first and the third month, respectively) in the all study group. uNGAL should be analyzed with more patients to assess as a predictive marker in the postrenal setting.

In the studies related to cut-off levels of uNGAL to predict severity, there are heterogeneous results. In our research, the uNGAL cut-off value was highest in the postrenal group (42.625 ng/mL). Wasilewska et al. presented a study, including children with obstructive nephropathy. They found that increase in uNGAL levels during the AKI course was associated with worsening obstruction, and it was independent of an increase in creatinine [19]. Since our entire pAKI patient group had a total bilateral urinary obstruction, it is likely that as uNGAL increases in the postrenal course, obstruction gets severe needing immediate urologic intervention. Our presented cut-off levels were lower than in other studies [4, 22,23], which would be related to a higher variability in the assay types used. In correlation analysis, we aimed to find whether spot uNGAL levels might show the renal prognosis after three months. We showed a significant but weak correlation between uNGAL levels and follow-up sCr levels (R² 10.5% and 16.9%, for the first and the third month, respectively) in the all study group. uNGAL should be analyzed with more patients to assess as a predictive marker in the postrenal setting.

This study has some limitations, like being a single-centered clinical trial study with a small sample size without additional follow-up of changes in uNGAL levels. Kostic et al. revealed that urinary biomarkers, alone and in combination, showed potential and noninvasive diagnostic tool for identifying infants with different levels of urinary obstruction who may benefit from earlier surgical intervention [24]. In our study, we did not analyze patients based on uNGAL levels after obstruction relief. Therefore, a large-scale, multicenter study is necessary to follow up on the biomarker level changes during the progress of obstructive nephropathy and confirm the value of uNGAL in renal prognosis monitoring.

In conclusion, patients with pre and postrenal AKI must be identified as soon as possible while their treatments are completely different. Missing information about the baseline sCr level often confounds the interpretation of a current elevated sCr concentration if obstruction is mild or not total. uNGAL as an AKI biomarker can be useful for facilitating a differential diagnosis of chronic conditions and intrinsic, prerenal, or postrenal etiologies at an early point. Patients with pAKI (unilateral and/or subtotal) may greatly benefit from early interventions that resolve obstruction before a severe AKI stage established. Future studies with high patient numbers will guide nephrologists and urologists in this setting.

Conflict of interest
The authors declare that they have no conflict of interest.

Informed consent
The study protocol was approved by the institution’s ethics committee (No. 2011-285) and was carried out under the Declaration of Helsinki. A signed informed parental consent form was obtained from all participants.
References

1. Rose BD. Pathophysiology of Renal Disease. 2nd ed. New York, NY, USA: McGraw-Hill; 1987. p. 41.

2. Fatehi P, Hsu C. Evaluation of acute kidney injury among hospitalized adult patients (last updated 02 October 2017). Palevsky PM (section editor), Sheridan AM (deputy editor). Waltham, MA, USA: UpToDate Inc. (Wolters Kluwer); 2018.

3. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements 2012; 2: 8-12. doi: https://doi.org/10.1038/kisup.2012.7

4. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A et al. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. American Journal of Kidney Diseases 2009; 54: 1012-1024. doi: 10.1053/j.ajkd.2009.07.020

5. Haase-Fielitz A, Bellomo R, Devarajan P, Bennett M, Story D et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrology Dialysis Transplantation 2009; 24: 3349-3354. doi: 10.1093/ndt/gfp234

6. Kümpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K et al. Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Critical Care 2010; 14 (1): 1-9. doi: 10.1186/cc8861

7. Herget-Rosenthal S. One step forward in the early detection of acute renal failure. Lancet 2005; 365 (9466): 1205-1206. doi: 10.1016/S0140-6736(05)74787-5

8. Soto K, Papoila AI, Coelho S, Bennett M, Ma Q et al. Plasma NGAL for the diagnosis of AKI in patients admitted from the emergency department settings. Clinical Journal of American Society of Nephrology 2013; 8 (12): 2053-2063. doi: 10.2215/CJN.12181212

9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N et al. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Annals of Internal Medicine 1999; 130: 461-470. doi: 10.7326/0003-4819-130-6-19990316-00002

10. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative Work Group. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004; 8: 204-212. doi: 10.1186/cc2872

11. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Journal of American Society of Nephrology 2013; 14 (10): 2534-2543. doi: 10.1097/01.asn.00000808027.54400.c6

12. Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase associated lipocalin for diagnosing acute kidney injury. Annals of Internal Medicine 2008; 148: 810-819. doi: 10.1036/0003-4819-148-11-200806030-00003

13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373-383. doi: 10.1016/0021-9681(87)90171-8

14. Ding H, Ye Y, Li K, Yang J, Li X et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clinical Immunology 2007; 123: 227-234. doi: 10.1016/j.clim.2007.01.010

15. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism 2006; 54: 2577-2584. doi: 10.1002/art.22008

16. Bolognino D, Crippolino G, Campo S, Aloisi C, Nicogia G et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. American Journal of Nephrology 2007; 27: 373-378. doi: 10.1159/000103912

17. Singer E, Elger A, Elitok S, Kettritz R, Nickolas TL et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-rexel from intrinsic renal failure and predicts outcomes. Kidney International 2011; 80: 405-414. doi: 10.1038/kj.2011.41

18. Urbschat A, Gauer S, Paulus P, Reissig M, Weipert C et al. Serum and urinary NGAL but not KIM-1 raises in human post-renal AKI. European Journal of Clinical Investigation 2014; 44 (7): 652-659. doi: 10.1111/eci.12283

19. Wasilewska A, Taranta-Janusz K, Debek W, Zoch-Zwierz W, Kuroczycka-Saniutycz E. KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatric Nephrology 2011; 26: 579-586. doi: 10.1007/s00467-011-1773-5

20. Madsen MG, Norregaard R, Palmfeldt J, Olsen LH, Frokiaer J et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney International 2012; 27: 2099-2106. doi: 10.1007/s00467-012-2217-6

21. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect renal damage. Pediatric Nephrology 2011; 26: 579-586. doi: 10.1007/s00467-011-1773-5

22. Alipour A, Mohammadjafari H, Rafiee A, Amjadi O. The role of urinary biomarker levels in assessing the presence and severity of ureteropelvic junction obstruction in children: a systematic review and meta-analysis. Journal of Pediatrics Review 2016; 4 (2): 1-11. doi: 10.17795/jpr.7567
23. Papachristou F, Pavlaki A, Printza N. Urinary and serum biomarkers in ureteropelvic junction obstruction: a systematic review. Biomarkers 2014; 19: 531-540. doi: 10.3109/1354750X.2014.943292

24. D Kostic, Beozzo GPNS, Do Couto SB, Kato AHT, Lima L et al. The role of renal biomarkers to predict the need of surgery in congenital urinary tract obstruction in infants. Journal of Pediatric Urology 2019; 15: 242-249. doi: 10.1016/j.jpurol.2019.03.009